In conclusion, our findings suggest a promising combination strategy for mutant p53 cancers in which the response to AF is synergistically enhanced by the addition of olaparib, although high concentrations of both compounds need to be reached to obtain a substantial cytotoxic effect. Here, TP53 is linked to cancer.